NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Phrontline Biopharma

Phrontline Biopharma

Private
ShanghaiHealthcare & Life Scienceshttps://phrontlinebio.com/

Last Round

pre_series_a_plus

Nov 25, 2025

Total Funding Raised

$60M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Phrontline Biopharma is a biotechnology company that develops innovative antibody-drug conjugates (ADCs) to address unmet medical needs in oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADConcology therapeuticssolid tumor treatmentbiotech licensingtargeted cancer therapydrug development partnershipclinical-stage biotechbiopharmaprecision medicinedrug discoverypharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phrontline Biopharma Comps

Public and private peers based on sector, stage, and business model.

Phrontline Biopharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Phrontline Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
pre_series_a_plusNov 25, 2025
Early FundingNov 21, 2025
VC RoundDec 25, 2023
AngelMar 10, 2022

Phrontline Biopharma Investors

Notable investors and investment history

Phrontline Biopharma investors
InvestorRounds
Jifeng VenturesEarly Funding, pre_series_a_plus
Lapam Capitalpre_series_a_plus
Samsung Venture InvestmentEarly Funding, pre_series_a_plus
C&D Emerging Industry Equity Investmentpre_series_a_plus
Medfine CapitalVC Round, Angel, pre_series_a_plus
Samsung Venture Investmentpre_series_a_plus
Hankang Capitalpre_series_a_plus

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 25, 2025

    Raised $60M in a pre-Series A+ round.

  • Oct 31, 2025

    Partnered with Sino Biopharmaceutical Limited for product TJ101 in China.

Phrontline Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phrontline Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phrontline Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range5
Year Founded2022
Last FundingNov 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.